

The **Standalone Financial Details of the Company** for the quarter ended 30th June 2025 and the preceding three previous years as per the audited statement of accounts are provided below:

Name of the Company: **Steriscience Specialties Private Limited**

(INR in Millions)

Particulars	For Quarter ended 30 th June 2025	As per last Audited Financial Year (FY 2024-25)	1 year prior to the last Audited Financial Year (FY 2023-24)	2 years prior to the last Audited Financial Year (FY 2022-23)
Equity Paid up Capital	0.21	0.21	0.19	0.19
Reserves and surplus	563.14	366.94	(35.04)	71.50
Carry forward losses*	-	-	-	-
Net Worth**	552.93	1664.22	(49.05)	44.95
Miscellaneous Expenditure	-	-	-	-
Secured Loans	439.84	455.73	3,595.7	2,208.49
Unsecured Loans	444.78	975.28	868	307.32
Fixed Assets [#]	0.29	47.8	2456.29	2716.14
Income from Operations	-	-	3,946.29	3,111.95
Total Income	265.25	95.33	4,068.43	3,167.15
Total Expenditure	37.05	328.23	4,164.43	3,573.96
Profit before Tax [§]	228.20	(232.9)	(96)	(406.81)
Profit after Tax [^]	196.45	(232.9)	(96)	(406.81)
Cash profit ^{&}	216.3	(102.62)	687.08	172.04
EPS	9412.58	11,692.91	(4,994.28)	(22,603.07)
Book value [%]	26,492.74	83,553.36	2,551.76	2,497.5

* Accumulated losses have been adjusted against Reserves and Surplus and therefore are not presented separately.

** Net Worth has been computed in accordance with the definition under Section 2(57) of the Companies Act, 2013.

[#] Fixed Assets includes Property, Plant & Equipment, Right of use assets, Capital work in progress, Other Intangible assets and Intangible assets under development.

[§] Profit before tax includes exceptional items.

[^] Profit after Tax is calculated without considering the other comprehensive income.

[&] Cash Profit has been derived by adding back depreciation and interest expenses to profit after tax.

[%] Book Value has been calculated as Net Worth divided by total number of outstanding shares.

T +91 80 6784 0000
F +91 80 6784 0700


 **Steriscience Specialties Private Limited**
CIN - U24304MH2020PTC424881
Reg. Off.: 201, Devavrata, Sector 17, Vashi
Navi Mumbai, Sanpada, Thane
Maharaashtra, India 400703
Corp off.: Chepha Block, First Floor, Sy No
152/6 & 154/16, Dorasani Palya, Begur Hobli
Bannerghatta Road, Bengaluru-560076





Note: Consolidated Financial Statement is not applicable to the Company.

For Steriscience Specialties Private Limited,


Chhitiz Saraogi
Director

Date: October 7, 2025



T +91 80 6784 0000
F +91 80 6784 0700



Steriscience Specialties Private Limited
CIN - U24304MH2020PTC424881
Reg. Off.: 201, Devavrata, Sector 17, Vashi
Navi Mumbai, Sanpada, Thane
Maharaashtra, India 400703
Corp off.: Chepha Block, First Floor, Sy No
152/6 & 154/16, Dorasani Palya, Begur Hobli
Bannerghatta Road, Bengaluru-560076



info@steri-science.com
www.steri-science.com



The **Standalone Financial Details of the Company** for the quarter ended 30th June 2025 and the preceding 3 previous years as per the audited statement of accounts are provided below:

Name of the Company: **Brooks Steriscience Limited**

(INR in Millions)

Particulars	For Quarter ended 30 th June 2025	As per last Audited Financial Year (FY 2024-25)	1 year prior to the last Audited Financial Year (FY 2023-24)	2 years prior to the last Audited Financial Year (FY 2022-23)
Equity Paid up Capital	3.14	3.14	2.24	2.24
Reserves and surplus	1,619.38	1,478.65	860.55	1,291.52
Carry forward losses*	-	-	-	-
Net Worth**	1,436.4	1,294.9	676.61	1106.69
Miscellaneous Expenditure	-	-	-	-
Secured Loans	389.42	470.31	459.2	139.66
Unsecured Loans	144.5	75.8	174.8	60.2
Fixed Assets [#]	1,633.73	1,629.06	1,542.25	1,411.48
Income from Operations	323.08	402.35	172.21	163.86
Total Income	324.95	411.01	177	164.45
Total Expenditure	183.45	676.01	503.18	522.66
Profit before Tax [§]	141.5	(265)	(326.18)	(358.21)
Profit after Tax [^]	141.5	(265)	(430.08)	(267.86)
Cash profit ^{&}	175.94	(116.96)	(300.68)	(176.43)
EPS	451	(1,167)	(1,916)	(1,284)
Book value [%]	4,580.47	5,700.01	3013.99	5306.36

* Accumulated losses have been adjusted against Reserves and Surplus and therefore are not presented separately.

** Net Worth has been computed in accordance with the definition under Section 2(57) of the Companies Act, 2013.

[#]Fixed Assets includes Property, Plant & Equipment, Right of use assets, Capital work in progress, Other Intangible assets and Intangible assets under development.

[§]Profit before tax includes exceptional items.

[^]Profit after Tax is calculated without considering the other comprehensive income.

[&]Cash Profit has been derived by adding back depreciation and interest expenses to profit after tax.

Corp. Off.:- 201, "The Summit Business Bay"
Behind Guru Nanak Petrol Pump,
Off Andheri Kurla Road, Andheri (E),
Mumbai - 400 093 (India)
Ph. : +91 22 69073100

%Book Value has been calculated as Net Worth divided by total number of outstanding shares.

***Note:** Consolidated Financial Statement is not applicable to the Company.*

For Brooks Steriscience Limited,

Atul Ranchal
Director

DIN: 01998361

Date: 6th October 2025

STERISCIENCE PTE. LIMITED

Company Registration Number: 202012334E

(The "Company")

(Incorporated in the Republic of Singapore)

Registered Office:

36 Robinson Road, #13-06 City House
Singapore 068877

Appendix – 8D

The **Standalone Financial Details of the Company** for the quarter ended 30th June 2025 and the preceding 3 previous years as per the audited statement of accounts are provided below:

Name of the Company: **Steriscience Pte. Ltd.**

(INR in Millions ^a)

Particulars	For Quarter ended 30 th June 2025	As per last Audited Financial Year (FY 2024-25)	1 year prior to the last Audited Financial Year (FY 2023-24)	2 years prior to the last Audited Financial Year (FY 2022-23)
Equity Paid up Capital	5,183.98	5,186.41	5,052.48	4,982.78
Reserves and surplus	(204.14)	(514.68)	(854.44)	(1,075.57)
Carry forward losses*	-	-	-	-
Net Worth**	4,979.85	4,671.73	4,198.04	3,907.22
Miscellaneous Expenditure	-	-	-	-
Secured Loans	1,149.75	999.55	519.55	581.62
Unsecured Loans	55.70	310.88	249.24	99.36
Fixed Assets [#]	1542.97	2,038.83	1,849.13	2,745.18
Income from Operations	1,594.12	2,350.56	4,229.01	2,750.99
Total Income	1,594.59	2,358.98	4,264.30	2,763.49
Total Expenditure	1,284.29	1,983.44	4,035.83	3879.24
Profit before Tax [§]	310.30	375.54	228.47	(1,115.75)
Profit after Tax [^]	310.30	375.54	228.47	(1,116.40)
Cash profit ^{&}	351.73	507.60	387.20	(1,061.24)
EPS	58.58	70.90	43.13	(210.76)
Book value [%]	940.11	881.95	792.52	737.62

^aThe US\$ Exchange Rate considered is: 85.54 (as on 30.06.25), 85.58 (as on 31.03.25), 83.37 (as on 31.03.24), and 82.22 (as on 31.03.23).

*Accumulated losses have been adjusted against Reserves and Surplus and therefore are not presented separately.

** Net Worth has been computed in accordance with the definition under Section 2(57) of the Companies Act, 2013.

[#]Fixed Assets includes Property, Plant & Equipment, Right of use assets, Capital work in progress, Other Intangible assets and Intangible assets under development.

[§]Profit before tax includes exceptional items.

[^]Profit after Tax is calculated without considering the other comprehensive income.

[&]Cash Profit has been derived by adding back depreciation and interest expenses to profit after tax.



STERISCIENCE PTE. LIMITED

Company Registration Number: 202012334E

(The "Company")

(Incorporated in the Republic of Singapore)

Registered Office:


36 Robinson Road, #13-06 City House

Singapore 068877

%Book Value has been calculated as Net Worth divided by total number of outstanding shares.

Note: Consolidated Financial Statement is not applicable to the Company.

For Steriscience Pte. Ltd.,


Chhitiz Saraogi
Director

Date: October 6, 2025



The **Standalone Financial Details of the Company** for the quarter ended 30th June 2025 and the preceding 3 previous years as per the audited statement of accounts are provided below:

Name of the Company: **Strides Pharma Services Private Limited**

(INR in Millions)

Particulars	For Quarter ended 30 th June 2025	As per last Audited Financial Year (FY 2024-25)	1 year prior to the last Audited Financial Year (FY 2023-24)	2 years prior to the last Audited Financial Year (FY 2022-23)
Equity Paid up Capital	1.85	1.85	1.85	1
Reserves and surplus	(1.85)	(1.77)	(1.6)	(1.27)
Carry forward losses*	-	-	-	-
Net Worth**	0.00	0.08	0.25	(0.27)
Miscellaneous Expenditure	-	-	-	-
Secured Loans	-	-	-	-
Unsecured Loans	-	-	-	0.51
Fixed Assets	-	-	-	-
Income from Operations	-	-	-	-
Total Income	-	0.03	-	-
Total Expenditure	0.07	0.2	0.33	1.27
Profit before Tax [§]	(0.07)	(0.17)	(0.33)	(1.27)
Profit after Tax [^]	(0.07)	(0.17)	(0.33)	(1.27)
Cash profit ^{&}	(0.07)	(0.16)	(0.27)	(1.24)
EPS (in INR)	(0.4)	(0.94)	(2.22)	(17.56)
Book value [%] (in INR)	0.02	0.42	1.69	(3.73)

* Accumulated losses have been adjusted against Reserves and Surplus and therefore are not presented separately.

** Net Worth has been computed in accordance with the definition under Section 2(57) of the Companies Act, 2013.

[§]Fixed Assets includes Property, Plant & Equipment, Right of use assets, Capital work in progress, Other Intangible assets and Intangible assets under development.

[§]Profit before tax includes exceptional items.


[^]Profit after Tax is calculated without considering the other comprehensive income.

[&]Cash Profit has been derived by adding back depreciation and interest expenses to profit after tax.

[%]Book Value has been calculated as Net Worth divided by total number of outstanding shares.

Note: Consolidated Financial Statement is not applicable to the Company.

For Strides Pharma Services Private Limited



Naveen Madan
Director
DIN: 10224023

Place: Bangalore
Date: 08/10/2025



Strides Pharma Services Private Limited

CIN: U74140KA2022PTC163606

Regd. Off. & Corp. Off.: 19/2, Sarakki Village, 15th Cross Road, Dollars Layout, JP Nagar 4th Phase, Bangalore 560078

Tel : +91 80 6784 0000 | E-mail ID : services@strides.com